{"id":1701,"date":"2022-11-21T13:43:25","date_gmt":"2022-11-21T12:43:25","guid":{"rendered":"https:\/\/avextra.com\/?page_id=1701"},"modified":"2026-03-06T11:50:53","modified_gmt":"2026-03-06T10:50:53","slug":"media","status":"publish","type":"page","link":"https:\/\/avextra.com\/it\/ueber-avextra\/media\/","title":{"rendered":"Media"},"content":{"rendered":"
Homepage<\/a><\/span><\/span>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n

Comunicati stampa<\/h1>\n\n\n\n

Qui trovate gli ultimi comunicati stampa di Avextra.<\/p>\n<\/div>\n\n\n\n

\n
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>
<\/div><\/div><\/div>
\"Neues<\/a><\/div>

Neues Dronabinol-Konzentrat optimiert Rezepturherstellung in der Apotheke<\/a><\/h3>

Bensheim, 5. Mai 2026 \u2013 Avextra erweitert mit dem Dronabinol Konzentrat Avextra 31 mg\/ml sein Portfolio an cannabisbasierten Rezepturarzneimitteln…<\/p>\n<\/div>

Ulteriori informazioni\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Novel<\/a><\/div>

Novel Pharmaceutical Avextra Capsule Enhances Patient Experience and Treatment Acceptance<\/a><\/h3>

Bensheim, Germany, December 3rd 2025 \u2014 How can therapy with Cannabis-based medicines (CbM) be designed to be not only therapeutically proven, but also patient-friendly and safe\u2026<\/p>\n<\/div>

Ulteriori informazioni\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Avextra<\/a><\/div>

Avextra supporta in Italia uno studio clinico di fase II sulla cannabis terapeutica nelle malattie neurodegenerative<\/a><\/h3>

Arruolato il primo paziente nello studio randomizzato, controllato con placebo\n\nBensheim, 24. ottobre 2025 \u2013 Le malattie neurodegenerative rappresentano una delle pi\u00f9 grandi sfide del nostro tempo. Solo in Germania vivono oggi...<\/p>\n<\/div>

Ulteriori informazioni\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"First<\/a><\/div>

First Patient Included Marks Major Milestone in EU-Funded Clinical Trial<\/a><\/h3>

Bensheim, Germany, August 11, 2025 \u2013\u00a0PsyPal has reached a major milestone with the inclusion of its first patient in the multi-site clinical trial investigating psilocybin…<\/p>\n<\/div>

Ulteriori informazioni\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Avextra<\/a><\/div>

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients<\/a><\/h3>

Bensheim, Germany, 13th June 2025 \u2014 New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines\u2026<\/p>\n<\/div>

Ulteriori informazioni\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Veteran<\/a><\/div>

Veteran Banker Joins Avextra\u2019s Supervisory Board<\/a><\/h3>

Bensheim, Germany, April 3, 2025 \u2013 Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra\u2019s Supervisory Board,…<\/p>\n<\/div>

Ulteriori informazioni\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Avextra<\/a><\/div>

Avextra Showcases Study Findings on World Sleep Day 2025<\/a><\/h3>

Bensheim, Germany \u2013 14 March 2025 \u2013 In anticipation of World Sleep Day, Avextra has revealed findings from its IMPACT study at the German Pain and Palliative Care Days, organised by the German Pain Association\u2026<\/p>\n<\/div>

Ulteriori informazioni\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Avextra<\/a><\/div>

Avextra Unveils Promising Study Results at Major Pain Congress<\/a><\/h3>

Bensheim, Germany \u2013 13 March 2025 \u2013 At its annual congress in Frankfurt, Germany, this week, researchers from the DGS will be presenting the results of the retrospective register study OCEAN-R, supported by Avextra\u2026<\/p>\n<\/div>

Ulteriori informazioni\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div><\/div>